Iloprost Zentiva

Iloprost, the active ingredient in Iloprost Zentiva, is a prostacyclin analog presented as an inhalation solution for inhalation use. It is indicated for the treatment of pulmonary arterial hypertension and for the management of digital ulcers associated with systemic sclerosis, providing vasodilatory and antiplatelet effects in affected patients.

GNH USA supplies Iloprost Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable global logistics to meet patient needs worldwide.

Iloprost acts on the prostacyclin pathway to treat severe vascular conditions.

Pulmonary arterial hypertension: improves hemodynamics and exercise capacity in patients with PAH. Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces pain. Pulmonary hypertension (group 1): reduces pulmonary arterial pressure and vascular resistance.

Iloprost may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Cough or throat irritation during inhalation. - Headache or flushing. - Nausea or mild abdominal discomfort. - Jaw or facial pain. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Significant hypotension or syncope. - Pulmonary edema or worsening respiratory distress. - Severe bleeding or thrombocytopenia. - Life‑threatening bronchospasm. - Cardiac arrhythmias or myocardial ischemia.

Before initiating therapy, clinicians should consider several safety measures.

Monitor blood pressure: watch for hypotension, especially after dose initiation. Assess bleeding risk: avoid use in patients with active hemorrhage or severe thrombocytopenia. Evaluate for pulmonary infection: respiratory infections may worsen with inhaled therapy. Use with caution in asthma or severe COPD: bronchospasm can be precipitated. Avoid concomitant use with other potent vasodilators without supervision. Store at room temperature: keep in original container, protect from moisture and light.

Iloprost can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Concurrent prostacyclin analogs: additive vasodilatory effect may cause severe hypotension. - Anticoagulants or antiplatelet agents: increased risk of bleeding. - Potent CYP450 inhibitors (if metabolized via CYP pathways): may raise plasma levels.

Moderate Interactions (Monitor Closely): - Phosphodiesterase‑5 inhibitors: may enhance pulmonary vasodilation. - Nitrates: additive blood pressure lowering effect. - Other antihypertensives: monitor for excessive hypotension. - Smoking or environmental irritants: may reduce inhaled drug efficacy.